Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma

A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Ansari, Jawaher, Hussain, Syed A, Ansari, Asif, Glaholm, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/
https://www.ncbi.nlm.nih.gov/pubmed/23467578
http://dx.doi.org/10.2147/BTT.S25862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588609/
https://www.ncbi.nlm.nih.gov/pubmed/23467578
http://dx.doi.org/10.2147/BTT.S25862

Ejemplares similares